IDENTIFYING LUNG FUNCTION DECLINE EARLY IS A TOP PRIORITY^3,20

REDUCED FVC IS ASSOCIATED WITH POOR OUTCOMES^9,10,21

In IPF – the prototypical progressive fibrosing ILD – reduction in FVC has been associated with poor outcomes, including decreased quality of life, increased hospitalizations, and increased mortality risk.^9-11,21 In many cases, diagnosis may be delayed, allowing progression to become more advanced.^1,22 FVC decline is an established measure of progression and surrogate marker for mortality.^6,20

LUNG FUNCTION LOSS IS CONTINUOUS AND CUMULATIVE⁶

Patients with IPF or PPF lose about 150 mL to 200 mL of lung function every year.^23,24 That means patients lose up to 7x more mL of lung function compared to those with normal physiological decline.^23-25

Lung function graph for IPF/PPF patients

As our understanding of IPF and PPF advances, collaboration across disciplines remains essential to identifying and monitoring the progression of pulmonary fibrosis.²⁶

FVC, forced vital capacity; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PPF, progressive pulmonary fibrosis.